This the first-in-human (FIH) study for the Investigational Medicinal Product (IMP) EP102, is designed to explore the maximum tolerated dose (MTD), the overall safety profile, its pharmacokinetic (PK) / pharmacodynamic (PD) profile, and an exploratory evaluation of antitumor activity in participants with advanced solid tumors, who have no available standard therapy or who have failed standard therapies.

This study will inform on recommended doses for further studies, e.g. dose optimization studies and / or efficacy and safety studies.

Inclusion Criteria:

• Participants must have a histological diagnosis of locally advanced or metastatic malignant solid tumors of one of the following cancer types:

  • ovarian cancer
  • cervical cancer
  • endometrial cancer
  • testicular cancer
  • cholangiocarcinoma
  • thyroid cancer
  • parathyroid cancer
  • adrenal cancer
  • pancreatic cancer
  • non-small-cell lung cancer (NSCLC)
  • head-and neck cancer
  • renal cell cancer
  • urethral cancer
  • bladder cancer
  • colorectal cancer
  • gastric cancer
  • esophageal cancer
  • triple-negative breast cancer
  • thymoma
  • soft tissue sarcoma

• Participants must have failed (i.e. progressed on, or been intolerant to standard treatment), or no standard treatment must exist, or they must have refused standard treatment. All participants must have received at least one prior line of systemic therapy.

• Participants must have at least one measurable lesion per RECIST v1.1.

• Participant must have a life expectancy of at least 12 weeks.

Exclusion Criteria:

• Participants with an active severe infection or unexplained fever > 38.5°C during screening or on the first day of study drug administration are excluded. However, at the Investigator's discretion, participants with tumor-related fever may be enrolled.
• Participants with known human immunodeficiency virus (HIV) infection, active hepatitis B virus (HBV) infection (hepatitis B surface antigen (HBsAg) positive in serum), or active hepatitis C virus (HCV) infection (HCV RNA positive in serum).
• Participants with known dysphagia, short-bowel syndrome, gastroparesis, or any condition that may impair the ingestion or gastrointestinal absorption of orally administered drugs.
• Pregnant or breastfeeding participants.
• Participants who have received IMP or devices in other clinical trials within four weeks before the first dose.
• Participants with prior exposure to selective METTL3 inhibitor therapy.

The sponsor will establish which IPD will be shared after the analysis of the study results

The sponsor will establish when the IPD will be shared after the analysis of the study results

The sponsor will establish the IPD access criteria after the analysis of the study results